<DOC>
	<DOCNO>NCT01182246</DOCNO>
	<brief_summary>The purpose study assess effect safety AXP107-11 alone , combination gemcitabine standard therapy , patient advance metastatic cancer pancreas . The safety , pharmacokinetics efficacy AXP107-11 patient also study .</brief_summary>
	<brief_title>AXP107-11 Combination With Standard Gemcitabine ( Gemzar® ) Therapy Treatment Patients With Pancreatic Cancer</brief_title>
	<detailed_description>The annual incidence rate pancreatic cancer almost identical mortality rate . Despite low incidence rate , pancreatic cancer fourth lead cause cancer mortality men woman . Today potentially curative option patient complete surgical resection . However , majority patient ( 80 % ) eligible surgery different reason . Today gemcitabine accept first-line treatment patient . Recent advance management pancreatic cancer suggest gemcitabine may improve combine anticancer drug . One attractive therapeutic option genistein . Genistein appear sensitize tumor chemotherapy target tumor cell also target component tumor microenvironment . However , limited bioavailability genistein know crystalline form lead difficulty attain adequate plasma concentration , result limited application dissemination clinical setting . To overcome limitation , novel crystalline form genistein improve pharmaceutical property use . AXP107-11 , crystalline salt genistein improve physiochemical property ( solubility , dissolution rate , bioavailability ) compare know crystalline form genistein . In study , AXP107-11 , investigate alone combination gemcitabine patient pancreatic cancer .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<criteria>1 . Age ≥ 18 year time signing inform consent 2 . Histologically confirm adenocarcinoma pancreas 3 . Metastatic locally advance , unresectable disease stage IIIIV . 4 . Measurable disease accord international criterion propose Response Evaluation Criteria Solid tumor ( RECIST ) target lesion 5 . Karnofsky Performance Status ≥ 70 study entry ( Appendix 18.4 ) . 6 . Life expectancy three month 7 . Negative pregnancy test female patient 8 . For fertile woman , willingness perform doublebarrier contraception study four week last treatment 9 . Able willing sign inform consent form 1 . Previous ongoing severe supraventricular ventricular arrhythmia 2 . Previous ongoing coagulation bleed disorder ( PTT &gt; 1.5 x ULN ) 3 . HIV infection 4 . Known hypersensitivity component AXP10711 formulation gemcitabine 5 . Previous ongoing significant liver pathology ( metastasis ) and/or liver function disorder 6 . Previous ongoing significant chronic renal dysfunction 7 . Previous ongoing malignancy pancreatic cancer &lt; five year prior enrolment , except basal cell carcinoma treat locally 8 . Cardiovascular disease , New York Heart Association ( NYHA ) classification III IV16 9 . Severe pulmonary obstructive restrictive disease 10 . Acute chronic inflammation ( autoimmune infectious ) 11 . Significant active/unstable nonmalignant disease likely interfere study assessment 12 . Laboratory test ( hematology , chemistry ) outside specify limit : WBC ≤ 3 x 10³/mm³ ANC ≤ 1.5 x 10³/mm³ Platelets ≤ 100.000/mm³ Hb ≤ 9.0 g/dl ( ≤ 5.6 mmol/l ) PT/PTT &gt; 1.5 x ULN Serum creatinine &gt; 130 μmol/l ) clearance &lt; 60 ml/min AST and/or ALT &gt; 3 x ULN exception patient liver metastasis ( &gt; 5 x ULN ) Alkaline phosphatase &gt; 3 x ULN Total bilirubin &gt; 3 x ULN 13 . Immunotherapy within six week prior enrolment . 14 . Any chemotherapeutical treatment pancreatic adenocarcinoma enrolment 15 . Any radiotherapy pancreatic adenocarcinoma enrolment except treatment bone metastases target lesion include irradiated field 16 . Major surgery within four week prior enrolment 17 . Pregnant nursing woman 18 . Participations interventional clinical study within four week enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>Pancreatic cancer</keyword>
</DOC>